Navigation Links
Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Date:4/2/2009

LAVAL, QC, April 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the results of its recently completed North American Phase III clinical trial for its twice-daily formulation of tramadol and acetaminophen (study 06CCL3-001).

Study 06CCL3-001 was a multi-centre, randomized, double-blind, parallel-arm study that compared the efficacy and safety of Labopharm's twice-daily tramadol-acetaminophen formulation to placebo in the treatment of moderate to severe acute low back pain. A total of 277 patients were included in the study. Thirteen percent (13%) of patients in the active treatment group discontinued early (12% due to adverse events) and 5% of patients in the placebo group discontinued early (2% due to adverse events).

Results of the efficacy measures in the study demonstrated a statistically significant difference from placebo in some cases but not in others. An analysis of covariance demonstrated a statistically significant difference from placebo on the Sum of Pain Intensity Differences (SPID) over 50 hours using LOCF (last observation carried-forward) as the imputation method, however, the results were not statistically significant using LOCF/BOCF (baseline observation carried-forward), the primary endpoint. A non-parametric analysis, however, demonstrated statistical significance using both LOCF and LOCF/BOCF as imputation methods. The difference from placebo on the Total Pain Relief (TOTPAR) score was also statistically significant using both LOCF and LOCF/BOCF imputation methods and the patients' global impression of the effectiveness of the study medication was statistically different from placebo. Statistical significance reflects a p-value of less than 0.05 in each of the analyses.

Regulatory authorities throughout the world have different requirements for the analysis and demonstration of efficacy in clinical trials. Labopharm believes that it is likely that the results of this trial are insufficient to support the acceptance of a New Drug Application (NDA) by the Food and Drug Administration (FDA) in the United States. The Company intends to discuss the matter with the FDA's Division of Anesthesia, Analgesia & Rheumatology Products (DAARP) to determine the path forward. The results of this study are however statistically significant under analyses that the Company believes may be accepted for the evaluation of analgesics in Europe, Canada and other jurisdictions. Accordingly, the Company intends to meet with the regulatory authorities for these jurisdictions at the earliest available opportunity in pursuit of regulatory approval. Should the authorities be in agreement, the Company expects that it would submit a regulatory application in those jurisdictions.

The Company will provide additional information following discussions with the various regulatory authorities.

The results of the study have no bearing on the upcoming launch of the Company's once-daily tramadol product in the United States.

About Tramadol-Acetaminophen Combination Products

Tramadol-acetaminophen products leverage the unique but complementary modes of action of each of the active ingredients to provide the analgesic strength of a mild opioid (tramadol) and the rapid pain relief of acetaminophen. Tramadol-acetaminophen combination products were first launched in 2001 in the United States and in 2003 in other major markets and are indicated for the short-term (five days or less) management of acute pain in the U.S. and the symptomatic treatment of moderate to severe pain in the rest of the world.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the price of the Company's shares, the uncertainties related to the regulatory process for drug approval and the commercialization of the Company's products, if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On ... Committee honored excellence in research, development and innovation in ... gala dinner was held in the presence of Sergey ... Russian Federation , Natalia Sanina, First ... Mikhail Murashko , Head of Roszdravnadzor, National Service of ...
(Date:12/2/2016)... CVS Health Corporation (NYSE: CVS ... City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). Senior ... an in-depth review of the company,s strategies to drive ... also discuss 2017 earnings guidance during the event. ... will be broadcast simultaneously on the Investor Relations portion ...
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite and the ... Dow Jones Industrial Average managed to stay in green. Losses ... prompted Stock-callers this morning to look at the performances of ... ), Smith & Nephew PLC (NYSE: SNN ), ... Therapeutics Inc. (NASDAQ: KOOL ). You can access ...
Breaking Medicine Technology: